{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:02:52Z","timestamp":1792029772858,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04381-w","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T16:44:20Z","timestamp":1737477860000},"page":"1945-1953","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness and safety of finerenone in membranous nephropathy patients: a retrospective, real\u2011world study"],"prefix":"10.1007","volume":"57","author":[{"given":"Haowen","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhe","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sichun","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"issue":"7","key":"4381_CR1","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41581-022-00564-1","volume":"18","author":"E Hoxha","year":"2022","unstructured":"Hoxha E, Reinhard L, Stahl RAK (2022) Membranous nephropathy: new pathogenic mechanisms and their clinical implications. Nat Rev Nephrol 18(7):466\u2013478. https:\/\/doi.org\/10.1038\/s41581-022-00564-1","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"4381_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1053\/j.ackd.2011.04.002","volume":"18","author":"MJ Sarnak","year":"2011","unstructured":"Sarnak MJ, Astor BC (2011) Implications of proteinuria: CKD progression and cardiovascular outcomes. Adv Chronic Kidney Dis 18(4):258\u2013266. https:\/\/doi.org\/10.1053\/j.ackd.2011.04.002","journal-title":"Adv Chronic Kidney Dis"},{"key":"4381_CR3","doi-asserted-by":"publisher","DOI":"10.1590\/2175-8239-JBN-2023-0046en","author":"M Dantas","year":"2023","unstructured":"Dantas M, Silva LBB, Pontes BTM, dos Reis MA, de Lima PSN, Moys\u00e9s Neto M (2023) Membranous nephropathy. Brazilian J Nephrol. https:\/\/doi.org\/10.1590\/2175-8239-JBN-2023-0046en","journal-title":"Brazilian J Nephrol"},{"key":"4381_CR4","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015111262","author":"DC Cattran","year":"2017","unstructured":"Cattran DC, Kim ED, Reich H, Hladunewich M, Kim SJ, for the Toronto Glomerulonephritis Registry, g. (2017) Membranous nephropathy: quantifying remission duration on outcome. J Am Soc Nephrol. https:\/\/doi.org\/10.1681\/ASN.2015111262","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"4381_CR5","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","volume":"66","author":"S Troyanov","year":"2004","unstructured":"Troyanov S, Wall CA, Scholey JW, Miller JA, Cattran DC (2004) Idiopathic membranous nephropathy: Definition and relevance of a partial remission. Kidney Int 66(3):1199\u20131205. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00873.x","journal-title":"Kidney Int"},{"key":"4381_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.021","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM et al (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"issue":"9868","key":"4381_CR7","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","volume":"381","author":"A Howman","year":"2013","unstructured":"Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J et al (2013) Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. The Lancet 381(9868):744\u2013751. https:\/\/doi.org\/10.1016\/S0140-6736(12)61566-9","journal-title":"The Lancet"},{"key":"4381_CR8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814427","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Reich JRHN, Parikh SV, Gipson DS, Lee DK, da Costa BR, J\u00fcni P, Cattran DC, Mentor Investigators (2019) Rituximab or cyclosporine in the treatment of membranous nephropathy. New England J Med. https:\/\/doi.org\/10.1056\/NEJMoa1814427","journal-title":"New England J Med"},{"issue":"6","key":"4381_CR9","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/s41440-022-00913-4","volume":"45","author":"M Mogi","year":"2022","unstructured":"Mogi M (2022) Aldosterone breakthrough from a pharmacological perspective. Hypertens Res 45(6):967\u2013975. https:\/\/doi.org\/10.1038\/s41440-022-00913-4","journal-title":"Hypertens Res"},{"issue":"3","key":"4381_CR10","doi-asserted-by":"publisher","first-page":"542","DOI":"10.2215\/CJN.04750908","volume":"4","author":"SD Navaneethan","year":"2009","unstructured":"Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GFMJC (2009) Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Amer Soc Nephrol 4(3):542\u2013551. https:\/\/doi.org\/10.2215\/CJN.04750908","journal-title":"Clin J Amer Soc Nephrol"},{"key":"4381_CR11","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S33759","author":"JL Guichard","year":"2013","unstructured":"Guichard JL, Clark Iii D, Calhoun DA, Ahmed MI (2013) Aldosterone receptor antagonists: current perspectives and therapies. Vascul Health Risk Manag. https:\/\/doi.org\/10.2147\/VHRM.S33759","journal-title":"Vascul Health Risk Manag"},{"issue":"10","key":"4381_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41569-023-00922-x","volume":"20","author":"G Filippatos","year":"2023","unstructured":"Filippatos G, Farmakis D (2023) Non-steroidal mineralocorticoid receptor antagonists in heart failure. Nat Rev Cardiol 20(10):645\u2013646. https:\/\/doi.org\/10.1038\/s41569-023-00922-x","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"4381_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T et al (2021) Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 42(2):152\u2013161. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa736","journal-title":"Eur Heart J"},{"key":"4381_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12104","author":"P Cravedi","year":"2013","unstructured":"Cravedi P, Remuzzi G (2013) Pathophysiology of proteinuria and its value as outcome measure in CKD. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.12104","journal-title":"Br J Clin Pharmacol"},{"key":"4381_CR15","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.02.335","author":"BL Neuen","year":"2021","unstructured":"Neuen BL, Weldegiorgis M, Herrington WG, Ohkuma T, Smith M, Woodward M (2021) Changes in GFR and albuminuria in routine clinical practice and the risk of kidney disease progression. Am J Kidney Dis. https:\/\/doi.org\/10.1053\/j.ajkd.2021.02.335","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"4381_CR16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/0886022x.2019.1605294","volume":"41","author":"X Chen","year":"2019","unstructured":"Chen X, Chen Y, Ding X, Zhou Y, Lv Y, Li D et al (2019) Baseline proteinuria level is associated with prognosis in idiopathic membranous nephropathy. Ren Fail 41(1):363\u2013369. https:\/\/doi.org\/10.1080\/0886022x.2019.1605294","journal-title":"Ren Fail"},{"issue":"12","key":"4381_CR17","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/s2213-8587(14)70194-9","volume":"2","author":"K Ando","year":"2014","unstructured":"Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T et al (2014) Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2(12):944\u2013953. https:\/\/doi.org\/10.1016\/s2213-8587(14)70194-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4381_CR18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040135","author":"N Juurlink David","year":"2004","unstructured":"Juurlink David N, Mamdani Muhammad M, Lee Douglas S, Kopp A, Austin Peter C, Laupacis A et al (2004) Rates of hyperkalemia after publication of the randomized aldactone evaluation study. New England J Med. https:\/\/doi.org\/10.1056\/NEJMoa040135","journal-title":"New England J Med"},{"issue":"23","key":"4381_CR19","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJM200412023512320","volume":"351","author":"W Md","year":"2004","unstructured":"Md W, Nd G, Ad S (2004) Hyperkalemia after the publication of RALES. N Engl J Med 351(23):2448\u20132450. https:\/\/doi.org\/10.1056\/NEJM200412023512320","journal-title":"N Engl J Med"},{"key":"4381_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000518254","volume":"52","author":"K Droebner","year":"2021","unstructured":"Droebner K, Pavkovic M, Grundmann M, Hartmann E, Goea L, Nordlohne J et al (2021) Direct blood pressure-independent anti-fibrotic effects by the selective nonsteroidal mineralocorticoid receptor antagonist finerenone in progressive models of kidney fibrosis. Am J Nephrol 52:1\u201314. https:\/\/doi.org\/10.1159\/000518254","journal-title":"Am J Nephrol"},{"issue":"4","key":"4381_CR21","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK et al (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4):S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"issue":"2","key":"4381_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"null, n.","year":"2023","unstructured":"null, n. (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388(2):117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"issue":"12","key":"4381_CR23","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","volume":"45","author":"P Rossing","year":"2022","unstructured":"Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL et al (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care 45(12):2991\u20132998. https:\/\/doi.org\/10.2337\/dc22-0294","journal-title":"Diabetes Care"},{"issue":"3","key":"4381_CR24","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/dom.15387","volume":"26","author":"T Eissing","year":"2024","unstructured":"Eissing T, Goulooze SC, van den Berg P, van Noort M, Ruppert M, Snelder N et al (2024) Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD. Diabetes Obes Metab 26(3):924\u2013936. https:\/\/doi.org\/10.1111\/dom.15387","journal-title":"Diabetes Obes Metab"},{"key":"4381_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03264-4","author":"M Vaduganathan","year":"2024","unstructured":"Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A et al (2024) Finerenone in Heart failure and chronic kidney disease with type 2 diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes. Nat Med. https:\/\/doi.org\/10.1038\/s41591-024-03264-4","journal-title":"Nat Med"},{"issue":"23","key":"4381_CR26","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"L Bakris George","year":"2020","unstructured":"Bakris George L, Agarwal R, Anker Stefan D, Pitt B, Ruilope Luis M, Rossing P et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"issue":"6","key":"4381_CR27","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","volume":"143","author":"G Filippatos","year":"2021","unstructured":"Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P et al (2021) Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation 143(6):540\u2013552. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051898","journal-title":"Circulation"},{"issue":"7","key":"4381_CR28","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1159\/000524940","volume":"53","author":"K Luettges","year":"2022","unstructured":"Luettges K, Bode M, Diemer JN, Schwanbeck J, Wirth EK, Klopfleisch R et al (2022) Finerenone reduces renal ROR\u03b3t \u03b3\u03b4 T cells and protects against cardiorenal damage. Am J Nephrol 53(7):552\u2013564. https:\/\/doi.org\/10.1159\/000524940","journal-title":"Am J Nephrol"},{"key":"4381_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-024-04142-1","author":"L Zhou","year":"2024","unstructured":"Zhou L, Li W (2024) Effectiveness and safety of finerenone in Chinese CKD patients without diabetes: a retrospective, real-world study. Int Urol Nephrol. https:\/\/doi.org\/10.1007\/s11255-024-04142-1","journal-title":"Int Urol Nephrol"},{"key":"4381_CR30","doi-asserted-by":"crossref","unstructured":"Osman, M. A., Ibrahim, K. S., Shah, N., Shojai, S., Okpechi, I. G., & Bello, A. K. (2022). Screening for chronic kidney disease. In evidence\u2010based nephrology (pp. 44\u201359).","DOI":"10.1002\/9781119105954.ch4"},{"issue":"1","key":"4381_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12882-018-0821-9","volume":"19","author":"KC Norris","year":"2018","unstructured":"Norris KC, Smoyer KE, Rolland C, Van der Vaart J, Grubb EB (2018) Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review. BMC Nephrol 19(1):36. https:\/\/doi.org\/10.1186\/s12882-018-0821-9","journal-title":"BMC Nephrol"},{"key":"4381_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213473","author":"ZC Dai","year":"2023","unstructured":"Dai ZC, Chen JX, Zou R, Liang XB, Tang JX, Yao CW (2023) Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1213473","journal-title":"Front Immunol"},{"key":"4381_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2020.07.022","author":"YT Chen","year":"2020","unstructured":"Chen YT, Chan CK, Li WY, Huang TM, Lai TS, Wu V et al (2020) Renin-angiotensin-aldosterone system inhibition decreased contrast-associated acute kidney injury in chronic kidney disease patients. J Formos Med Assoc. https:\/\/doi.org\/10.1016\/j.jfma.2020.07.022","journal-title":"J Formos Med Assoc"},{"key":"4381_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110210","author":"Q Chen","year":"2023","unstructured":"Chen Q, Liang Y, Yan J, Du Y, Li M, Chen Z et al (2023) Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: A systematic review and meta-analysis. Diabetes Res Clin Pract. https:\/\/doi.org\/10.1016\/j.diabres.2022.110210","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"4381_CR35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","volume":"18","author":"J Barrera-Chimal","year":"2022","unstructured":"Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F (2022) Mineralocorticoid receptor antagonists in diabetic kidney disease \u2014 mechanistic and therapeutic effects. Nat Rev Nephrol 18(1):56\u201370. https:\/\/doi.org\/10.1038\/s41581-021-00490-8","journal-title":"Nat Rev Nephrol"},{"issue":"24","key":"4381_CR36","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker Stefan D, Bakris George L, Rossing P et al (2021) cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385(24):2252\u20132263. https:\/\/doi.org\/10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"issue":"14","key":"4381_CR37","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1113\/jphysiol.2011.209692","volume":"589","author":"M Fila","year":"2011","unstructured":"Fila M, Brideau G, Morla L, Cheval L, Desch\u00eanes G, Doucet A (2011) Inhibition of K+ secretion in the distal nephron in nephrotic syndrome: possible role of albuminuria. J Physiol 589(14):3611\u20133621. https:\/\/doi.org\/10.1113\/jphysiol.2011.209692","journal-title":"J Physiol"},{"key":"4381_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010044","author":"P Ria","year":"2023","unstructured":"Ria P, De Pascalis A, Zito A, Barbarini S, Napoli M, Gigante A et al (2023) Diet and proteinuria: state of art. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24010044","journal-title":"Int J Mol Sci"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04381-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04381-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04381-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T14:12:51Z","timestamp":1746281571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04381-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["4381"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04381-w","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been corrected. Order of institution in affiliation 1 is corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no commercial or financial relationships that could be construed as potential conflicts of interest in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study followed the ethical guidelines of Guangdong Provincial People's Hospital, with the ethical approval number KY2024-722\u201301.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}